Exelixis Has Good News for Metastatic Castration-Resistant Prostate Cancer

Exelixis Announced Results from its CABOMETYX® Combination with Roche's TECENTRIQ®
News announced by Exelixis (EXEL) about encouraging results from the combination of its product cabozantinib (CABOMETYX®) with Roche’s product atezolizumab (TECENTRIQ . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.